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Avenanthramides (AVAs) present in oats are amides of anthranilic and cinnamic acids. AVAs are potent antiox-
idants and have anti-inflammatory properties. There are various potential mechanisms for their anti-inflammatory
effects, including inhibition of lipoxygenases (LOX), which catalyse oxygenation of polyunsaturated fatty acids
into potent signal molecules involved in inflammatory processes. In this study, AVAs were screened for LOX
inhibition in vitro and structure-activity relationships were examined. Twelve different AVAs at 0.6 mM were
tested as LOX inhibitors. The corresponding free cinnamic acids, the AVA analogue Tranilast® and the known LOX
inhibitor trans-resveratrol were included for comparison. It was found that AVAs comprising caffeic or sinapic acid
exhibited significant lipoxygenase inhibition (60–90%) (P < 0.05), whereas low or no inhibition was observed
with AVAs containing p-coumaric or ferulic acid. No difference in inhibition was seen on comparing AVAs with
their free corresponding cinnamic acids, which implies that the anthranilic acid part of the avenanthramide
molecule does not affect inhibition. Trans-resveratrol showed inhibition, whereas no inhibition was seen for
Tranilast® at the concentrations used in this study. This study suggests that aventahtramides comprising caffeic
acid or sinapic acid partly exert their antioxidant and anti-inflammatory effects via lipoxygenase inhibition.1. Introduction
Lipid oxidation is an important process in many different biological
systems. In a food context, lipid oxidation is one of the major causes of
food deterioration, as it may lead to off-flavours, changes in colour and
texture and also decreased nutritional value of food products (Cro-
guennec; 2016). Lipid oxidation can proceed in either a non-enzymatic or
an enzymatic fashion. Lipoxygenases (LOX) constitute a family of
non-haem iron-containing enzymes that catalyst oxidation of fatty acids
and are widely distributed in plants and animals (Hildebrand, 1989;
Kuhn et al., 2015; Horn et al., 2015). In plants, the substrate is mainly
linoleic acid (LA) (C18:2, n-6) and α-linolenic acid (ALA) (C18:3, n-3),
whereas in mammals it is arachidonic acid (AA) (C20:4, n-6). In mam-
mals vegetable LA can be transformed to AA though enzyme mediated
elongation and desaturation reactions. The same reactions also transform
ALA to eicosapentaenoic acid (EPA, C20:5, n-3) and docosahexaenoic
acid (DHA, C22:6, n-3). Lipid oxidation can be a problem in living sys-
tems, by altering the function of membranes and lipoprotein particles
(Kuhn et al., 2015). In mammalian cells, LOX catalyse the initial step in
the conversion of AA to the hydroperoxide, 5-hydroperoxy-6,8,11,berg).
January 2020; Accepted 22 Jun
vier Ltd. This is an open access ar14-eicostatetraenoic acid, and are thereby key enzymes in the biosyn-
thesis of a variety of bio-regulatory compounds such as leukotrienes
(Pergola and Werz, 2010; H€aggstr€om and Funk, 2011; Rådmark et al.,
2015). Leukotrienes are considered to be potent mediators of
pro-inflammatory reactions. LOX enzymes are also associated to
biosynthesis of compounds which may promote termination of acute
inflammation reactions, and thereby function as anti-inflammatory
agents. Such compounds are for example lipoxins, which are bio-
synthesised via oxygenation of AA, and resolvins, biosynthesised though
oxygenation of the ω-3 fatty acids EPA and DHA (Pirault and B€ack, 2018;
Recchiuti et al., 2019; Kuhn et al., 2015; Rådmark et al., 2015). Acute
inflammation is a protective process. However, overbalance of
pro-inflammatory vs anti-inflammatory agents over time may result in a
variety of chronic inflammatory diseases, such as arthritis, bronchial
asthma, and cardiovascular diseases (Yoon and Baek, 2005; Pergola and
Werz, 2010; Chen, 2011; H€aggstr€om and Funk, 2011; Kuhn et al., 2015;
Bruno et al., 2018). Therefore, inhibition of the pro-inflammatory LOX
pathway is suggested to be interesting for prevention of these disesases.
Many of the LOX inhibitors are found among the class of phenolic com-
pounds, which have radical scavenging and/or iron chelating properties,e 2020
ticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
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Bucar, 2005a, 2005b; Pergola and Werz, 2010; Chen, 2011).
Avenanthramides (AVAs) belong to a group of phenols comprising
anthranilic and cinnamic acid derivatives (Figure 1a; Table 1). Among
cereals, AVAs are found only in oats and so far 15 compounds have been
identified (Dimberg et al., 1993; Matsukawa et al., 2000; Bratt et al.,
2003; Collins, 2011; Ishihara et al., 2014; Readelli et al., 2015; Pridal
et al., 2018; de Bruijn et al., 2019). The three most abundant AVAs in oat
groats are 2p, 2f and 2c, the 2 indicating 5-hydroxyanthranilic acid (as
opposed to 1 for anthranilic acid, 3 for 5-hydroxy-4-methoxyanthranilic
acid, 4 for 4-hydroxy anthranilic acids and 5 for 4,5-dihydroxyanthra-
nilic acid), and the p, f and c indicating the cinnamic acids p-coumaric,
ferulic and caffeic acid, respectively (Bratt et al., 2003; Fagerlund
et al., 2009; Dimberg and Jastrebova, 2009; Ishihara et al., 2014; Readelli
et al., 2015; de Bruijn et al., 2019). Other AVAs with cinnamic acids
replaced by the corresponding avenalumic acids (5-phenyl-penta-2,4
dienoic) are also present in oats (Dimberg and Jastrebova, 2009; Collins,
2011; Ishihara et al., 2014; Pridal et al., 2018; de Bruijn et al., 2019).
Sinapic acid (s) is found in oats, but no AVAs derived from this acid
have been found in oat plant (Bratt et al., 2003; Collins, 2011).a
b
Figure 1. Structures of compounds used in the experiments: a) avenan-
thramides (1s, 2s and 3s are not found in oats), Tranilast®, and cinnamic acids
(see Table 1 for the substitution pattern of the molecular skeletons) and b) trans-
resveratrol.
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Consumption of oats has been linked to a decreased risk of several
chronic diseases and it has been suggested that AVAs contribute to the
protective effects (Meydani, 2009; Tripathi et al., 2018). In in vitro
studies, AVAs have been characterised as antioxidants with a clear
structure-activity relationship (Dimberg et al., 1993; Bratt et al., 2003;
Fagerlund et al., 2009; Lee-Manion et al., 2009; Ishihara et al., 2014).
They have also been shown to be bioavailable (Zhang et al., 2017) and to
exert antioxidant activity in vivo (Ji et al., 2003; Chen et al., 2004, 2007;
Koenig et al., 2014). Furthermore, they have been found to exhibit
anti-inflammatory, anti-proliferative and anti-itch activities in vitro and in
vivo (Nie et al., 2006a, 2006b; Sur et al., 2008; Koenig et al., 2014;
Reynertson et al., 2015; Hastings and Kenealey, 2017; Scarpa et al.,
2018). In a food context, AVAs have been shown to be correlated to the
fresh oat taste of oat products (Molteberg et al., 1996).
In this study it is hypothesized that AVAs partly protect oat foods from
rancidity development through inhibition of LOX activity. Furthermore,
a hypothesis is that AVAs may inhibit LOX and/or cyclooxygenase (COX-
2) enzymes in mammals and thereby decrease the production of pro-
inflammatory compounds, such as leukotrienes and prostaglandins. An
AVA-enriched oat extract has been shown to inhibit cyclooxygenase
(COX-2) activity and pro-inflammatory prostaglandin production from
AA in mouse macrophages (Guo et al., 2010). Furthermore, a butanolic
fraction of oat groats has been found to have anti-platelet activities
mediated though inhibition of the COX and LOX pathways (Ahmed et al.,
2013). The authors of the latter study did not speculate about the possible
compounds involved, but a high amount of AVAs is probably present in a
butanol extract, since methanol and ethanol are good extracting solvents
for AVAs (Dimberg and Jastrebova, 2009).
The aim of the present work was to investigate whether pure AVAs
and their corresponding free cinnamic acids (Figure 1a; Table 1), have
LOX inhibitor activity in vitro. A further aim was to establish a structure-
inhibition activity relationship. Trans-resveratrol (Fig. 1b), a phenolic
stilbene known to possess LOX inhibitor activity (Fan and Mattheis,
2001; Chatterjee et al., 2011), was used as a positive control. Tranilast®
(Figure 1a; Table 1), a known non-phenolic drug with anti-inflammatory
properties (Pae et al., 2008; Darakhshan and Pour, 2015) and with
remarkable chemical similarities to the AVAs was used as a negative
control (Komatsu et al., 1988).
2. Materials and methods
2.1. Chemicals
Lipoxygenase, LOX 1 from soybean, (EC 1.13.11.12), was purchased
from SIGMA Chemicals Co. (St. Louis, MO, USA), linoleic acid from
Calbiochem® (U.S and Canada), sinapic acid from Fluka Chemie AG
(Buchs SG, Switzerland) and ferulic-, caffeic- and p-coumaric acid from
SIGMA Chemicals Co. (St. Louis, MO, USA). All AVAs were synthesised
according to Bratt et al. (2003) (1- and 2-series) or Fagerlund et al.
(2009) (3-series). All other chemicals used were pro analysi and were
used without further purification.
2.2. HPLC analysis
Reverse-phase high performance liquid chromatography (RP-HPLC)
analysis was performed with an HP series 1100 instrument (Hewlett
Packard, Waldbronn, Germany) equipped with diode array detector
(DAD) and a HP ODS Hypersil column (5 μm, 125 mm  4 mm). The
isocratic mobile phase was acetonitrile:0.01M phosphate buffer (pH 2.8)
containing 5% acetonitrile (70:30). Sample size injected was 10 μL and
the flow rate was 1 mL/min. Products of LOX activity were detected at
234 nm (Villafuerte Romero and Barrett, 1997). Peaks were identified
from retention times (Figure 2) and UV-spectra, and were manually in-
tegrated using the software HP ChemStation Version 05.01.
Table 1. Structures of compounds used in the experiments (refers to Figure 1a).
R1 R2 R3 R4 R5
Avenanthramide1
1p H H H OH H
2p OH H H OH H
3p OH OCH3 H OH H
1f H H OCH3 OH H
2f OH H OCH3 OH H
3f OH OCH3 OCH3 OH H
1c H H OH OH H
2c OH H OH OH H
3c OH OCH3 OH OH H
1s H H OCH3 OH OCH3
2s OH H OCH3 OH OCH3
3s OH OCH3 OCH3 OH OCH3
Tranilast® H H OCH3 OCH3 H
Cinnamic acid
p H OH H
f OCH3 OH H
c OH OH H
s OCH3 OH OCH3
1 1: anthranilic acid; 2: 5-hydroxyanthranilic acid; 3: 5-hydroxy-4-methoxyanthranilic acid; p: p-coumaric acid; f: ferulic acid; c: caffeic acid; s: sinapic acid.
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Enzyme solution was prepared by thoroughly mixing 4 μL enzyme
with 20 mL 0.1 M borate buffer (Na3(BO)3/HCl), pH 9. Substrate solution
was prepared by dispersing 15 μL linoleic acid in 60 mL 0.1 M borate
buffer (pH 9) containing 15 μL Tween 20, shaking thoroughly and then
sonicating for 1min. AVAs, Tranilast®, trans-resveratrol and the cinnamic
acid derivatives were prepared as 9 mM stock-solutions in ethanol/
borate buffer (15/85). All solutions were used promptly to avoid
autoxidation and degradation of enzyme.2.4. LOX assay
Enzyme solution (100 μL) was mixed with 200 μL of a stock-solution
of the test compound and the mixture was incubated for 10 min. Then 2.7
mL of linoleic acid solution were added and the mixture was vortexed
and incubated in a 30 C water bath for 30 min. The enzymatic reaction
was stopped by adding 100 μL of concentrated hydrochloric acid. The
reaction mixture was extracted with 3.0 mL of ethyl acetate. A 2 mL
sample of the organic phase was collected and evaporated to dryness in a
centrifuge evaporator. The solid residue was dissolved in 200 μL of
methanol and analysed by HPLC. As a control sample, ethanol/buffer
solution without added test compound was used. In addition, a control in
which hydrochloric acid was added to the enzyme solution prior to
linoleic acid, in order to inactivate the enzyme, was included (Figure 2).
In order to compare inhibition of the different compounds, the same
molar concentration (0.6 mM) in the final test solution was used in all
tests. In a pre-test it was found that 0.6 mM was appropriate for ca 50%
inhibition of the enzyme activity when using caffeic acid as the inhibitor.
For practical reasons, the controls and four test compounds were
analysed in each experiment. Seven experiments (A-G) were performed
to study the structure-LOX-inhibition activity relationships for AVAs/
cinnamic acids. In the first four experiments (A-D), the importance of the
substitution pattern in the antranilic acid part of the AVAs was eluci-
dated, i.e. the cinnamic acid part was the same within each experiment.
The following three experiments (E-G) studied the influence of the sub-
stitution pattern in the cinnamic acid part of the compounds, i.e. the
anthranilic acid part was the same within each experiment (due to lack of
material, the experiment with the 3-series was omitted). The inhibition3
capacity of Tranilast® and trans-resveratrol was tested in one additional
experiment (H).
Since the enzyme activity in the buffer solution decreased with time,
and to avoid autoxidation of the substrate each experiment was per-
formed with freshly prepared enzyme and substrate solutions. Enzyme
activity was measured as the amount of conjugated dienes formed from
linoleic acid, expressed as area units. The inhibition was calculated as the
enzyme activity difference between reaction with and without added test
compound. Since the enzyme activity slightly differed between the ex-
periments, inhibition was expressed as percentage of uninhibited sample
within each experiment.
2.5. Statistics
Analysis of variance with Tukey's pairwise comparison (α¼ 0.05) was
conducted using the software Minitab release 11.12 (Minitab Inc., State
College, PA). Each experiment (A-H) was run separately with three rep-
licates of each compound (except for 2s in experiment G, which was run
with two replicates). All comparisons were made within each experiment
(A-H) since the conditions between experiments varied somewhat.
3. Results
The lipoxygenase activity expressed as the relative amount of con-
jugated diene formed from linoleic acid in the presence of the test
compounds is shown in Figure 3, where each letter (A-H) represents one
experiment.
3.1. Structure-activity relationship of LOX inhibition
3.1.1. Influence of the anthranilic acid moiety
No significant difference in inhibition activity was found between the
free cinnamic acids p-coumaric acid (p), ferulic acid (f), caffeic acid (c)
and sinapic acid (s) and their corresponding AVAs (Figure 3, experiments
A-D), except that s showed significantly higher inhibition than 3s.
Moreover, no differences were foundwithin the 1-, 2- or 3- series of AVAs
(experiments A-D) except for 2f, which exerted slightly higher inhibition
than 3f, and for 3s, which showed lower inhibition than 1s and 2s.
Compared to controls, the p-serie inhibited the LOX enzyme 0–30%
(experiment A), the f-serie 0–20% (experiment B), the c-serie 50–70%
Figure 2. Reverse-phase chromatogram of lipoxygenase products detected at 234 nm of a) an active lipoxygenase enzyme and b) an inactivated lipoxygenase enzyme.
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indicate that the anthranilic acid part of the avenanthramides was of
minor importance for the inhibition.
3.1.2. Influence of the cinnamic acid moiety
Among the free cinnamic acids, caffeic (c) and sinapic (s) acids
showed significant inhibition of LOX activity (60–90%) compared to the
control, whereas p-coumaric (p) and ferulic (f) acids showed low or no
inhibition (Figure 3, experiments A-D, E). The difference in inhibition
between c and swas not significant (experiment E). A similar pattern was
observed when the 1-series of AVAs was studied (experiment F), i.e. 1c
and 1s significantly inhibited LOX, whereas 1p and 1f did not. Again,
there was no significant difference between the inhibition of 1c and 1s.
The experiment with the 2-series of avenanthramides showed that 2c and
2s, but also 2f, had significant inhibitory effects and that all were
significantly different in their activity, following the order 2s > 2c > 2f
(experiment G). The LOX activity was approximately 1.2 times higher in
the sample with AVA 2p compared with the control (experiment G).
However, this was not observed in experiment A. The 3-series could not
be evaluated in this context, due to lack of material. However, from ex-
periments A-D it was evident that 3c and 3s inhibited the LOX activity by4
50–60% and 3p inhibited it by around 30%, whereas no inhibitory ac-
tivity was found for 3f. This confirms that the cinnamic acid part of the
AVAs, especially those containing caffeic and sinapic acids, was impor-
tant for LOX inhibition.
3.1.3. Controls
Trans-resveratrol was an effective lipoxygenase inhibitor when pre-
sent in the assay at a concentration of 0.60 mM, but Tranilast® was not
(Figure 3, experiment H).
4. Discussion
Although it has been shown that different phenols have LOX-
inhibiting activity, the mechanisms involved have not been fully identi-
fied. In the active form of LOX, there is a ferric ion (Fe3þ) at the active
site. When linoleic acid is oxidised, the electron from the hydrogen atom
is transferred to Fe3þ and its proton to a proton acceptor. The Fe3þ ion is
thus reduced to a ferrous ion (Fe2þ), rendering the enzyme inactive. The
linoleic acid radical formed is re-arranged to a conjugated diene radical,
which reacts with oxygen to form a peroxy radical. The peroxy radical
reacts further with a proton and the electron from Fe2þ to form a
Figure 3. Products formed after lipoxygenase (LOX) activity on linoleic acid in the presence of avenanthramides, their corresponding cinnamic acids, Tranilast® or
trans-resveratrol at 0.6 mM, expressed as percentage of controls (uninhibited samples). Each capital letter (A–H) represents one experiment. Error bars are given as
coefficient of variation (CV) (except for 2s in experiment G, which is given as the difference between the two replicates). Different superscript letters within each
experiment A-H indicate significant differences (p < 0.05) between the compounds tested.
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activated and the reaction can re-start with another linoleic acid (Hil-
debrand, 1989; H€aggstr€om and Funk, 2011). The mechanism of LOX
inhibition can be explained in several ways, e.g. the inhibitor may
scavenge the linoleic acid radicals formed, it may chelate or reduce the
Fe3þ ion in the active site of the enzyme, or it may interact with the
enzyme molecule.
Caffeic and sinapic acids and their corresponding AVAs were the most
efficient inhibitors in the present study. These compounds are also strong
antioxidants when tested in diphenylpicrylhydrazyl (DPPH) and non-
enzymatic linoleic acid diene formation assays (Bratt et al., 2003;5
Fagerlund et al., 2009; Lee-Manion et al., 2009; Ishihara et al., 2014),
both of which methods rely on a radical scavenging mechanism. The
stronger antioxidation activity of c and s derivatives found was expected,
as they are able to stabilise the phenolic radical formed better than p and
f derivatives. However, if the enzymatic inhibition shown in the present
study had been caused solely by radical scavenging, the 3-series of AVAs
would have been expected to be more active than the 2-series, which in
turn would have been more active than the 1-series. This was not the
case. Instead, it was found that there was no significant difference be-
tween the free cinnamic acids and their corresponding avenanthramides
from the 1-, 2- and 3-series (Figure 3, experiments A-D). We therefore
R. Landberg et al. Heliyon 6 (2020) e04304suggest that chelation of the Fe3þ iron within the active site of the
enzyme is important. However, it seems that a phenolic structure is also
important, since the non-phenolic molecule Tranilast®, with the same
basic skeleton as the AVAs (Figure 1 a; Table 1), did not have any
inhibitory properties under the test conditions. Tranilast® is an
anti-inflammatory substance (Komatsu et al., 1988; Pae et al., 2008;
Darakhshan and Pour, 2015), but the anti-inflammatory activity appears
to be dependent on other mechanisms rather than through LOX inhibi-
tion. Other studies have also demonstrated that cinnamic acid analogues
lacking the redox-active phenolic hydroxyl groups lose all LOX inhibitory
activity and that radical scavenging is not sufficient to ensure efficient
LOX inhibition (Doiron et al., 2017; Touaibia et al., 2018).
We could not determine whether the inhibition observed in the pre-
sent study was caused by an interaction between the phenolic com-
pounds and the enzyme, since the initial velocity of product formation
was not monitored. However, it is unlikely that the active compounds
acted as competitive inhibitors, since their structures are very different
from that of the substrate, i.e. linoleic acid. Nevertheless, other in-
teractions between inhibitors and the enzymemay occur, as other studies
have shown that caffeic acid derivatives exert both non-competitive
(Koshihara et al., 1984) and uncompetitive (Sud'ina et al., 1993) inhi-
bition. These compounds have also been reported to inhibit the enzyme
by chelating iron ions, thereby preventing catalysis (Young, 1999).
We recognize that high concentrations of AVAs have been used in our
in vitro experiments. AVAs are bioavailable (Chen et al., 2004, 2007;
Zhang et al., 2017), but whether dietary AVAs at intake levels normally
achieved through consumption of oat products exert LOX inhibitory ac-
tivity in vivo, and thereby inhibit production of pro-inflammatory com-
pounds, remains to be elucidated. In this context it may also be of
importance to emphasize that the lipid content in groats of various oat
cultivars is comparably high (49–135 g kg1) and that LA and ALA
comprise about 40% and 1%, respectively, of the fatty acids present
(Bryngelsson et al., 2002; Sterna et al., 2016). Theoretically, this may
imply that oat derived LA, as a precursor to AA, could adversely affect the
inflammatory processes and thereby counteract the possible protective
effect of the avenanthramides. However, studies performed on healthy
humans consuming a Western diet, have failed to show that additional
dietary intake of LA is positively associated with pro-inflammation
markers, such as e.g. interleukin-6 (Il-6), interleukin-1β (IL-1β), tumour
necrosis factor (TNF-α) and c-reactive protein (CRP) in the plasma (Innes
and Calder, 2018; Fritsche, 2015).
In conclusion, AVAs have been shown to possess anti-inflammatory
properties and the present study provides in vitro findings suggesting
that this could be due to inhibition of LOX activity. These findings,
together with findings from previous studies on antioxidant activity
(Dimberg et al., 1993; Bratt et al., 2003; Fagerlund et al., 2009; Lee--
Manion et al., 2009; Ishihara et al., 2014), may indicate that oat AVAs
(especially the c-derivatives, as s-derivatives are not found in oats) can
protect oat foods from rancidity development and contribute to
anti-inflammatory effects in mammals. Further studies on foods and in
vivo studies in mammals are needed to confirm this.
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